摘要
目的:比较罗格列酮和二甲双胍治疗多囊卵巢综合征的临床疗效。方法:80例氯米芬抵抗的多囊卵巢综合征患者,随机分为罗格列酮组40例和二甲双胍组40例,疗程为6个月,比较两组用药前、后体重指数、月经周期、生殖激素水平、排卵率、妊娠率、血糖和胰岛素水平的变化。结果:①罗格列酮和二甲双胍均可降低血LH/FSH比值和雄激素水平(P<0.05),恢复卵巢排卵功能;②罗格列酮可降低HomaIR指数和Homaβ指数(P<0.05),二甲双胍降低BMI评分(P<0.05)。结论:罗格列酮和二甲双胍均可改善氯米芬抵抗的多囊卵巢综合征患者生育功能;但罗格列酮改善胰岛素抵抗优于二甲双胍,而降低体重作用二甲双胍优于罗格列酮。
Objective： To compare the clinical efficacy of Rosiglitazone and Metforrnin on insulin action, hirsutism and anovulatory infertility in women with polycystic ovarian syndrome （PCOS） and clomiphene citrate （CC） resistance. Methods： 80 PCOS subjects were randomized to Rosiglitazone group （40 cases） and Meforrnin group （40cases）. Rosiglitazone and Metforrnin were respectively administered for 6 months in combining with CC on the 5～9th day of the menstrual cycle. The clinical features, reproductive hormone, serum glucose and insulin levels were observed before and after treatment. The data were analyzed using repeated analysis of variance （ANOVA）. Resuits： After treatment, there was significantly reduction in the hirsutism score, serum LH and testosterone level, and LH/FSH ratio in Metforrnin group and Rosiglitazone group（both P〈0.05）, and restoration of ovarian ovulation improved in two groups also. Insulin sensitivity has significantly been improved in the Rosiglitazone group compared to Metforrnin group （P〈0.05） after treatment. Homa IR and Homaβ were decreased more in Rosiglitazone. Mean BMI was decreased more in Metforrnin group than in Rosiglitazone group （P〈0.05）. Conclusions： Rosiglitazone improves insulin sensitivity better but Metforrnin reduces BMI better. They all restore regular menstrual cycles, increase pregnancy rate, and decrea..se serum testosterone and LH concentration in women with polycystic ovarian syndrome accompanied CC resistance.
出处
《实用妇产科杂志》
CAS
CSCD
北大核心
2005年第9期541-544,共4页
Journal of Practical Obstetrics and Gynecology
基金
陕西省科学技术发展基金资助项目(2003K10G65)
